Gor, A. P., Dalal, K. B., Ganguly, B. P.
Drug-drug interaction between active pharmacological ingredients is a significant criterion for evaluation of rationality of fixed dose combinations (FDCs). Being combination therapy is useful as treatment of cardiac disorders, there have been umpteenth cardiovascular FDCs marketed in India. Aim of this study was evaluation of drug-drug interactions of cardiovascular FDCs enlisted in CDSCO list from 2009 to 2015. According to inclusion criteria, 51 such cardiovascular FDCs from CDSCO were selected for analysis. Scientific evidence for cardiovascular FDCs was assessed using accessible electronic and print sources like Medscape and standard textbooks and descriptive statistics was applied. Maximum numbers of FDCs 19 (37.25%) were enlisted in CDSCO from 2010. All fixed dose combinations 51 (100%) from cardiovascular system were having oral dosage form. Fixed dose combinations 40 (78.43%) were having 2 active pharmacological ingredients. There were 17 (33.33%) combinations found to be Pharmacodynamic drug interaction whereas 3 combinations were having pharmacokinetic interactions between active pharmacological ingredients (APIs). There have been many numbers of FDCs approved by CDSCO in comparison with WHO essential medicine list and national list of essential medicines. Adverse DDIs between API of FDCs can increase morbidity and economic burden of patients. To lower the frequency of potential interactions, it could be necessary to make a careful selection of therapeutic alternatives and in cases without other options, patients should be continuously monitored to identify adverse events.
Fixed dose combinations, Drug-drug interactions, Cardiovascular
Cite This Article
Gor, A. P., Dalal, K. B., & Ganguly, B. P. (2015). Evaluation of Drug-Drug Interactions between Active Pharmacological Ingredients of Fixed Dose Combinations of Cardiovascular System Enlisted in CDSCO List, International Journal for Pharmaceutical Research Scholars (IJPRS), 4(4), 167-172.